Lipella Pharmaceuticals Inc

LIPO11 Dec 2024
Healthcare
$2.99
-0.01 (-1.32%)
Lowest Today
$2.91
Highest Today
$3.08
Today’s Open
$2.99
Prev. Close
$3.03
52 Week High
$10.4
52 Week Low
$2.21
To Invest in Lipella Pharmaceuticals Inc

Lipella Pharmaceuticals Inc

Healthcare
LIPO11 Dec 2024
-0.01 (-1.32%)
1M
3M
6M
1Y
5Y
Low
$2.91
Day’s Range
High
$3.08
2.91
52 Week Low
$2.21
52-Week Range
52 Week High
$10.4
2.21
1 Day
-
1 Week
+8.27%
1 month return
-3.52%
3 month return
+645.04%
6 month return
+361.65%
1 Year return
+242.27%
3 Years return
-
5 Years return
-
10 Years return
-
Institutional Holdings
Sabby Management LLC
5.59
Vanguard Group Inc
0.36
Vanguard Institutional Extnd Mkt Idx Tr
0.36
Geode Capital Management, LLC
0.27
Fidelity Extended Market Index
0.25
Tower Research Capital LLC
0.08
Spartan Extended Market Index Pool E
0

Market Status

Fundamentals
Market Cap
3.57 mln
PB Ratio
2.38
PE Ratio
0
Enterprise Value
2.19 mln
Total Assets
3.58 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.
Organisation
Lipella Pharmaceuticals Inc
Employees
5
Industry
Biotechnology
CEO
Dr. Jonathan  Kaufman M.B.A., Ph.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step